

# NYRx Drug Class Coverage Overview: Glucagon-Like Peptide-1 Agonists

## NYRx Preferred Drugs

Drugs in the Glucagon-Like Peptide-1 (GLP-1) agonists drug class are included on the [NYRx Preferred Drug List \(PDL\)](#) and are subject to prior authorization (PA) requirements of the [NYRx Drug Utilization Review \(DUR\) Program](#):

Preferred Drugs	Non-Preferred Drugs	Prior Authorization/Coverage Parameters
<b>VI. Endocrine and Metabolic Agents</b>		
<b>Glucagon-like Peptide-1 (GLP-1) Agonists <sup>CC</sup></b>		
Byetta® Ozempic® Trulicity® Victoza® <sup>BLTG</sup>	Bydureon® BCise™ liraglutide (gen Victoza®) Mounjaro® Rybelsus® Soliqua® Xultophy®	<b>CLINICAL CRITERIA (CC)</b> <ul style="list-style-type: none"> <li>Confirm diagnosis of FDA-approved, compendia-supported, and Medicaid-covered indication</li> </ul>

## Prior Authorization Requirements

- Preferred drugs will not require PA if the required coverage parameters are found in the member’s Medicaid claim history at the time of pharmacy claim submission. Providers should include all applicable diagnosis codes in a member’s electronic medical record (EMR) and submit their claims in a timely manner to decrease the need to manually obtain a PA.
- Non-preferred drugs will require PA.
- All drugs in the GLP-1 agonists drug class are subject to Clinical Criteria (CC). CC must confirm the diagnosis of FDA-approved, compendia-supported, Medicaid-covered indication.

**Note:** NYRx, the Medicaid pharmacy program, covers medically necessary FDA-approved drugs when used for Medicaid-covered indications. Certain drugs, drug classes, or drug indications including weight loss are excluded from coverage pursuant to federal or state law and regulation. Exclusions include agents when used for the treatment of anorexia, weight loss, or weight gain [18 NYCRR§505.3(g)(3)]. Weight loss is not and never has been a Medicaid-covered indication. GLP-1 agonists, including but not limited to Ozempic, Wegovy, and Mounjaro are excluded from coverage for weight loss indications. Editing has been enhanced to ensure that members with Medicaid-covered indications have access to these medications. For more information, please refer to the [NYRx Excluded Diagnoses](#).

- NYRx does not cover more than one GLP-1 agonist or more than one strength of the same GLP-1 agonist at a time. To reduce overutilization, stockpiling, and/or diversion of drugs, pharmacies will receive a rejection when submitting claims for more than one GLP-1 agonist or more than one strength of the same GLP-1 agonist while the patient still has greater than 25% of a current fill remaining.

## What Pharmacy Providers Need to Do

- Proper claim submission: Claims for GLP-1 agonists should be submitted based on the total days' supply for the quantity dispensed. For example, a prescription with a quantity of 4 to be administered once per week should be submitted as a 28-day supply. Failure to submit claims with accurate days' supply may result in claim rejection.
- Pharmacy providers should become familiar with the NYRx GLP-1 agonists coverage criteria and the [PDL](#) and incorporate this information when discussing the need for PA with prescribers.
- Dose titration: subsequent prescriptions for dose titration will not pay until 25% or less supply of the previous prescription remains.

## What Prescribers Need to Do

- Prescribers should become familiar with the GLP-1 agonists coverage criteria and the [PDL](#) and incorporate this information when prescribing for Medicaid members.
- If a prescriber determines a need to switch the patient's treatment or dose while the patient still has greater than 25% of a current fill remaining, the prescriber may request a prior authorization from the NYRx clinical call center.

## Resources

- [NYRx Education & Outreach Website](#)
- [NYRx Excluded Diagnoses](#)
- [NYRx Preferred Drug List](#)
- [NYRx Prior Authorization Form](#)
- [NYRx Prior Authorization Submission Guide](#)

## Contact Information

The NYRx Education & Outreach Call Center is available by phone at 1-833-967-7310 or by email at [NYRxEO@primetherapeutics.com](mailto:NYRxEO@primetherapeutics.com) from 8:00 AM to 5:00 PM ET, Monday through Friday, excluding holidays.

The NYRx Education & Outreach team hosts virtual office hours every week for stakeholders to ask questions related to NYRx and care coordination. Visit the [NYRx Education & Outreach website](#) for more information.